Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. CONTACT:hello@jaguar.healthJaguar-JAGXSOURCE: Jaguar Health, Inc.View source version on accesswire.com:https://www.accesswire.com/798255/issuance-of-new-us-patent-bolsters-ip-protection-for-jaguar-health-in-the-treatment-of-short-bowel-syndrome-sbs

Source: The North Africa Journal November 01, 2023 18:54 UTC